A Review of Margetuximab-Based Therapies in Patients with HER2-Positive Metastatic Breast Cancer

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Breast cancer (BC) is a leading cause of cancer mortality worldwide.
• HER2-targeted therapies have improved outcomes for HER2-positive BC, but resistance remains a challenge in metastatic disease.
• Novel therapeutic strategies are crucial for overcoming resistance and improving survival in HER2-positive metastatic breast cancer (MBC).

Purpose of the Study:

• To review the efficacy and clinical utility of margetuximab for treating HER2-positive breast cancer.
• To discuss the mechanism of action of margetuximab, focusing on its modified Fc domain.
• To present recent advances in breast cancer treatment and the implications of margetuximab in HER2+ MBC.

Main Methods:

• Literature review of studies on margetuximab efficacy and clinical trials.
• Analysis of margetuximab's Fc domain modifications and their impact on CD16A and CD32B binding.
• Synthesis of current research on HER2-positive breast cancer treatment strategies.

Main Results:

• Margetuximab's Fc domain optimization enhances binding to CD16A and reduces binding to CD32B, leading to increased antitumor activity.
• Studies indicate margetuximab's potential as an effective anti-HER2 monoclonal antibody for HER2+ BC.
• The review highlights margetuximab's role in addressing treatment resistance in HER2+ MBC.

Conclusions:

• Margetuximab represents a significant advancement in targeted therapy for HER2-positive breast cancer.
• Its unique Fc domain engineering offers a promising approach to overcome resistance to conventional anti-HER2 drugs.
• Margetuximab holds clinical implications for improving treatment outcomes in patients with HER2-positive metastatic breast cancer.